Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope (Q40281145)

19 September 2017

title

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope (English)

1 reference

19 September 2017

7

John R Mascola

1 reference

19 September 2017

8

Gary J Nabel

1 reference

19 September 2017

2

Zhi-Yong Yang

1 reference

19 September 2017

4

Brent Welcher

1 reference

19 September 2017

5

Sarah Winfrey

1 reference

19 September 2017

Lan Wu

1

1 reference

19 September 2017

Ling Xu

series ordinal

3

1 reference

19 September 2017

Yiming Shao

series ordinal

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

18 April 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

24

1 reference

19 September 2017

issue

23

1 reference

19 September 2017

page(s)

4995-5002

1 reference

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Identifying epitopes of HIV-1 that induce protective antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Identification of HIV vaccine candidate peptides by screening random phage epitope libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Antibodies, viruses and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

HIV evolution: CTL escape mutation and reversion after transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Evolution and transmission of stable CTL escape mutations in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Escape of human immunodeficiency virus from immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Priming characteristics of peptide mimotopes of carbohydrate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Plasmid immunization primes unique DTH responses to HIV-1MN envelope epitopes as compared to recombinant protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.03.083

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.03.083

1 reference

19 September 2017

1 reference